Abstract
Dopaminergic drugs exert their action through activation of dopamine D1 and D2 receptors [1]. Changes of dopamine receptor density or affinity following antiparkinsonian drug therapy is suggested to underlie the development of long-term treatment complications in patients with PD [2]. However, evidence for this has not been provided.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Schachter M, Bedard P, Debono AG, et al. The role of D1 and D2 receptors. Nature 1980;286:57–159
Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson’s disease: central pathophysiological mechanism, part II. Ann Neurol 1988;24;372–378
Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986;231:258–261
Wachtel H. Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. J Neural Transm Park Dis Dement Sect 1991;3:151–201
Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson’s disease. Neurology 1989;39:336–339
Antonini A, Schwarz J, Oertel WH, Beer HG, Madeja UD, Leenders KL: [11C] Raclopride and positron emission tomography in previously untreated patients with Parkinson’s disease: Influence of L-Dopa and Lisuride therapy on striatal dopamine D2 receptors. Neurology 1994;44:1325–1329
Ehrin E, Gawell L, Högberg T, Paulis T, Ström P. Synthesis of (methoxy-3H)- and (methoxy-11C)-labeled raclopride-specific dopamine D2 receptors ligands. J Labelled Compounds Radiopharmaceuticals 1987;24:931–9398.
Volkow ND, Fowler JS, Wang GJ, et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 1993;34:609–613
Rinne UK. Early use of dopamine agonist in the treatment of Parkinson’s disease. In: Rinne UK, Nagatsu T, Horowski R, editors. Parkinson’s disease. How to proceed today in treatment. Bussum: Medicom,1991; 326–336
Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine treated rats. Brain Research 1990;525: 36–44
Young LT, Wong DF, Goldman S, et al. Kinetic effects of increased endogenous dopamine levels on [3H]-NMSP and [3H]-raclopride binding in rat brain: relevance to PET imaging (abstract). J Cereb Blood Flow Metab 1991;11(suppl 2):S870
Leenders KL, Salmon EP, Tyrrel P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson’s disease. Arch Neurol 1990;47:1290–1298
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Leenders, K.L., Antonini, A. (1995). Lisuride and [C-11]-Raclopride Interaction at the D2 Receptor Site. In: Comar, D. (eds) PET for Drug Development and Evaluation. Developments in Nuclear Medicine, vol 26. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-0429-6_19
Download citation
DOI: https://doi.org/10.1007/978-94-011-0429-6_19
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4191-1
Online ISBN: 978-94-011-0429-6
eBook Packages: Springer Book Archive